Literature DB >> 16466332

Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature.

Deidre B Clark1, Miranda R Andrus, Debbie C Byrd.   

Abstract

A 47-year-old woman developed confusion, incoordination, and hypertension after she was given linezolid in addition to sertraline for 5 days. Her symptoms resolved within 4 days of discontinuing linezolid. One and a half months later, she received a second course of linezolid; sertraline was discontinued on day 1 of linezolid therapy. On day 9 of therapy, the patient developed confusion, myoclonus, and incoordination, and cardiopulmonary arrest occurred, leaving the patient in a coma. Diarrhea, hypertension, and tachycardia developed after cardiopulmonary arrest. Linezolid was discontinued on day 10, and cyproheptadine was given. Linezolid is a weak monoamine oxidase inhibitor and has been reported to interact with selective serotonin reuptake inhibitors (SSRIs). Several cases of serotonin syndrome in patients taking linezolid and SSRIs have been reported, including two reports with sertraline, one with paroxetine, four with citalopram, and two with fluoxetine. One abstract of a retrospective analysis reported that serotonin syndrome did not occur in patients who received linezolid and fluoxetine, paroxetine, or sertraline. Because of several limitations, however, no conclusions can be drawn from that retrospective analysis. A drug interaction involving escitalopram and linezolid has not been documented. Caution should be used when linezolid is used in patients receiving an SSRI. Other antibiotic options should be considered first, and linezolid should be reserved as the last resort if possible. If the infection requires linezolid, the SSRI should be discontinued, and the patient should be monitored closely for serotonin syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466332     DOI: 10.1592/phco.26.2.269

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  Linezolid and serotonin syndrome.

Authors:  Davin K Quinn; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

2.  Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data.

Authors:  Clare Ringland; Andrea Mant; Patricia McGettigan; Philip Mitchell; Christopher Kelman; Nicholas Buckley; Sallie-Anne Pearson
Journal:  Br J Clin Pharmacol       Date:  2008-07-08       Impact factor: 4.335

Review 3.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

4.  Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors:  P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 5.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

6.  Linezolid-induced serotonin syndrome.

Authors:  Anish Shouan; Rajeet Kumar; Vivek Lal; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2021-03-15

7.  Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literature.

Authors:  Lampros Samartzis; Paraskevi Savvari; Sofoklis Kontogiannis; Stavros Dimopoulos
Journal:  Case Rep Psychiatry       Date:  2013-03-04

8.  Update on the appropriate use of linezolid in clinical practice.

Authors:  Roberto Manfredi
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

9.  Linezolid-induced near-fatal serotonin syndrome during escitalopram therapy: case report and review of literature.

Authors:  Ranganath R Kulkarni; Pratibha R Kulkarni
Journal:  Indian J Psychol Med       Date:  2013-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.